Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease (Q37031522)

17 August 2017

1 reference

title

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease (English)

1 reference

17 August 2017

0 references

1

Ramón Cacabelos

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Molecular Diagnosis and Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

11

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

385-405

1 reference

Pharmacogenetics goes genomic

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

The impact of the completed human genome sequence on the development of novel therapeutics for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenetics and pharmacogenomics: development, science, and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Impact of genomics on drug discovery and clinical medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

The application of functional genomics to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenomics in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenomics for the treatment of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenomics and therapeutic prospects in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Deciphering the genetic basis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

A century of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Gene-environment interactions in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Caliban's heritance and the genetics of neuronal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Epigenetic mechanisms in memory formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Reliability and Validity of NINCDS-ADRDA Criteria for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Finishing the euchromatic sequence of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacogenetics for the individualization of psychiatric treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Relationship of deep white matter hyperintensities and apolipoprotein E genotype to depressive symptoms in older adults without clinical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Vascular disease/risk and late-life depression in a Korean community population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Catalog of 680 variations among eight cytochrome P450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Drug discovery in dementia: the role of rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Cytochrome P450 in the brain; a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

PM frequencies of major CYPs in Asians and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Pathological gambling and dopamine agonists: A phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

CYP2D6 gene test in psychiatric patients and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E epsilon 4 effect modification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Comparison studies of cholinesterase inhibitors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Measuring the value of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FBF03256262

21 January 2018

12 December 2020

Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Apolipoprotein E gene polymorphism in early and late onset bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256262

Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.

21 January 2018

1 reference

12 December 2020

Molecular genetics of Alzheimer's disease and aging

1 reference

12 December 2020

Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population

1 reference

12 December 2020

Genomics and phenotypic profiles in dementia: implications for pharmacological treatment

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men.

1 reference

12 December 2020

1 reference

12 December 2020

Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics

1 reference

12 December 2020

Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease

1 reference

12 December 2020

No association between familial Alzheimer disease and cytochrome P450 polymorphisms.

1 reference

12 December 2020

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

12 December 2020

Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype

1 reference

12 December 2020

Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics.

1 reference

12 December 2020

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

A pharmacogenomic approach to Alzheimer's disease.

1 reference

12 December 2020

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

1 reference

12 December 2020

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

1 reference

12 December 2020

Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.

1 reference

12 December 2020

Depression in Alzheimer's disease might be associated with apolipoprotein E epsilon 4 allele frequency in women but not in men

1 reference

12 December 2020

Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.

1 reference

12 December 2020

1 reference

12 December 2020

CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease.

1 reference

12 December 2020

Clinical proteomics: present and future prospects.

1 reference

12 December 2020

Behavioral changes associated with different apolipoprotein E genotypes in dementia.

1 reference

12 December 2020

Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256262

1 reference

17 August 2017

1 reference